Maqbul Jamil

M. Jamil is a commercial leader in the Pharmaceutical industry with two decades of strategic and operational experience in matrix organizations across geographies, Jamil has extensively worked with clinical development teams to commercialize breakthrough therapeutics, including the first small molecule targeted therapy and the first aPD-1 immunotherapy. Jamil is currently working at Merck & Co and is responsible for the commercialization of oncology pipeline assets. He is also an adjunct Professor at Columbia Business School in New York. Previously Jamil worked in marketing and commercial roles of increasing responsibility at Bayer, Eli Lilly and Novartis in US, Europe, Middle East and Emerging Markets to launch multiple products in numerous therapeutic areas. Jamil got his Ph.D. in Marketing from Kelley School of Business, Indiana University.